Statement: the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified.
Primary_evidence: INTERVENTION 1:    Active Medicine Group   risedronate 35 mg weekly INTERVENTION 2:    Placebo Group   Received placebo medication once weekly
Secondary_evidence: INTERVENTION 1:    Standard Chemotherapy   Patients receive cyclophosphamide-containing chemotherapy alone.   cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2:    Chemotherapy Plus Goserelin   Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.   cyclophosphamide: Part of planned chemotherapy regimen   goserelin acetate: Given subcutaneously